Aquavit Pharmaceuticals, Inc. has launched a cutting-edge technology the AQUAGOLD® fine touch™. It is a first-of-its-kind direct dermal application technology.
Helen Maddock, a scientist from the Centre for Applied Biological and Exercise Sciences at Coventry University, UK, has developed a new technique to safely test a drug's cardiovascular effects without testing initially before they even reach animal or human trials.
The new breakthrough technique called ‘simulated’ cardiovascular system, also known as a work-loop assay, ensures that drugs are tested and determines the negative effects of certain drugs in the early stages.
This realistic heart muscle dynamic modeluses samples of beating heart tissueattached to a rig that allows the muscle to lengthen and shorten while being stimulated by an electrical impulse. And then, scientists can add trial drugs to the tissue and see if there is any negative effect on the contraction of the muscles in the heart.
This confirms drugs are tested before they even reach animal or human trials.
The new technique uses an in vitro method- meaning ‘in glass,’ as it is carried out in a lab environment rather than in a living organism. This is intended to improve the quality of treatment and save hundreds of patients' lives.
